Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

Abstract: A crystal unit is provided with a rectangular substrate, a frame which is provided on an upper surface of the substrate, a mounting frame which has joining pads which are provided along the outer circumferential edge of the upper surface and which is provided on the lower surface of the substrate by joining joining terminals provided along the outer circumferential edge of the lower surface of the substrate and its joining pads, a crystal element which is mounted on electrode pads which are provided on the upper surface of the substrate in a region surrounded by the frame, a thermosensitive element which is mounted on connection pads which are provided on the lower surface of the substrate in a region surrounded by the mounting frame, and a lid which is joined to the upper surface of the frame.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.

Abstract: A rear opening is provided in the rear part of a vehicle, and a tailgate opens and closes the rear opening. A spoiler is provided at the upper end of the tailgate. Deflectors are provided below the spoiler. The deflectors extend downward along the outer surface of the tail gate from the lower surface of the spoiler and are disposed at positions offset by a predetermined distance from the opposite ends in the vehicle width direction of the spoiler toward a central portion in the vehicle width direction of the spoiler.

Abstract: A reset controller is adopted which performs control for causing an external reset terminal to be shared for external output of a reset signal and input of a reset signal from outside, allowing a reset input from the external reset terminal in a state in which a power supply voltage is stable, and causing, when a reset factor due to turn-on of a power supply voltage or a reduction in the level of the power supply voltage is detected by a detection circuit, an input/output buffer to output a reset signal to the external reset terminal and masking the inflow of the reset signal from the input/output buffer to its input path, using a signal detected by the detection circuit. A mask period is assumed to be a period longer than a period from reset instructions to a reset release.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: A rear opening is provided in the rear part of a vehicle, and a tailgate opens and closes the rear opening. A spoiler is provided at the upper end of the tailgate. Deflectors are provided below the spoiler. The deflectors extend downward along the outer surface of the tail gate from the lower surface of the spoiler and are disposed at positions offset by a predetermined distance from the opposite ends in the vehicle width direction of the spoiler toward a central portion in the vehicle width direction of the spoiler.

Abstract: The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: A crystal unit is provided with a rectangular substrate, a frame which is provided on an upper surface of the substrate, a mounting frame which has joining pads which are provided along the outer circumferential edge of the upper surface and which is provided on the lower surface of the substrate by joining terminals provided along the outer circumferential edge of the lower surface of the substrate and its joining pads, a crystal element which is mounted on electrode pads which are provided on the upper surface of the substrate in a region surrounded by the frame, a thermosensitivel element which is mounted on connection pads which are provided on the lower surface of the substrate in a region surrounded by the mounting frame, and a lid which is joined to the upper surface of the frame.

Abstract: A reset controller is adopted which performs control for causing an external reset terminal to be shared for external output of a reset signal and input of a reset signal from outside, allowing a reset input from the external reset terminal in a state in which a power supply voltage is stable, and causing, when a reset factor due to turn-on of a power supply voltage or a reduction in the level of the power supply voltage is detected by a detection circuit, an input/output buffer to output a reset signal to the external reset terminal and masking the inflow of the reset signal from the input/output buffer to its input path, using a signal detected by the detection circuit. A mask period is assumed to be a period longer than a period from reset instructions to a reset release.

Abstract: A reset controller is adopted which performs control for causing an external reset terminal to be shared for external output of a reset signal and input of a reset signal from outside, allowing a reset input from the external reset terminal in a state in which a power supply voltage is stable, and causing, when a reset factor due to turn-on of a power supply voltage or a reduction in the level of the power supply voltage is detected by a detection circuit, an input/output buffer to output a reset signal to the external reset terminal and masking the inflow of the reset signal from the input/output buffer to its input path, using a signal detected by the detection circuit. A mask period is assumed to be a period longer than a period from reset instructions to a reset release.